A large-scale, collaborative, systems biology approach is needed to expedite the discovery of treatments for dry age-related macular degeneration, according to a report by a working group of scientists appointed by the National Advisory Eye Council (NAEC) that includes Joan. W. Miller, MD, Chair of Harvard Ophthalmology.
New research led by Kip Connor, PhD, finds that microglia—the primary immune cells of the central nervous system, including the retina—play a vital role in regulating neuroinflammation in autoimmune uveitis. The study, published in Proceedings of the National Academy of Sciencesand featured on eyewire News, may one day lead to better treatment targets for the disease.
In the preclinical model of autoimmune uveitis, the researchers describe, for the first time, a role for microglia in directing the initiation of autoimmune uveitis by orchestrating the inflammatory response within the retina. In reaction to disease induction, microglia closely associate with the retinal vasculature and facilitate inflammatory immune cell entry past the blood brain, or ocular, barrier into the retina. When the researchers depleted microglia in this model, they observed that the disease was completely blocked.
On September 2018, a Harvard Ophthalmology delegation traveled to China to meet with PriMed, Peking University Medical Hospital, and the Center of International Cooperation & Communication of Peking University Health Science Center.... Read more about Academic Partnerships with China Continue
In a significant advance against drug-resistant superbugs, investigators supported by the Harvard-wide Program on Antibiotic Resistance have identified a new class of synthetic antibiotics that have been shown to be effective against Staphylococcus aureus and Enterococcus. The newly discovered antibiotics could one day help treat deadly infections caused by these superbugs.
As part of the Association for Research in Vision and Ophthalmology (ARVO) and National Alliance for Eye and Vision Research (NAEVR) Advocacy Day, Magali Saint-Geniez, PhD, and Russell Woods, PhD, two vision researchers from Schepens Eye Research Institute at Mass. Eye and Ear/Harvard Ophthalmology,...
Findings may lead to earlier diagnoses and better prognostic information for patients — and, potentially, new pharmaceutical targets for AMD treatment.
Boston, Mass. — Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through special laboratory tests, according to a new study led by AMD researchers based at Massachusetts Eye and Ear. The study, ...